FDA Adverse Event Injury Summary report: N

TAXUS¿ ELEMENT¿

MDR report key: 2253498 · Received September 19, 2011

Report

Report Number
2134265-2011-04145
Event Type
Injury
Date Received
September 19, 2011
Date of Event
August 19, 2011
Report Date
August 22, 2011
Manufacturer
BOSTON SCIENTIFIC - GALWAY
Product Code
NIQ
PMA / PMN Number
P100023
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
FR
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4).

Additional Manufacturer Narrative · 1

PATIENT IDENTIFIER: (B)(6). DEVICE IS A COMBINATION PRODUCT DEVICE EVALUATED BY MANUFACTURER: IT IS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION; THEREFORE A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. A REVIEW OF THE BATCH HISTORY, HISTORICAL TRENDING, AND SIMILAR COMPLAINT TRENDING REVIEW FOR THE PRODUCT FAMILY WILL BE CONDUCTED. IF THERE IS ANY FURTHER RELEVANT INFORMATION FROM THAT REVIEW, A SUPPLEMENTAL MEDWATCH WILL BE FILED. (B)(4).

Description of Event or Problem · 1

IT WAS FURTHER REPORTED THAT THE SITE HAS CHANGED THEIR ASSESSMENT OF DEVICE RELATIONSHIP TO UNRELATED.

Description of Event or Problem · 1

(B)(4). IT WAS REPORTED THAT FOLLOWING A CORONARY ARTERY STENTING TREATMENT PROCEDURE THE PATIENT EXPERIENCED A MYOCARDIAL INFARCTION. THE TARGET LESION WAS LOCATED IN THE MID LEFT ANTERIOR DESCENDING ARTERY WITH 80% STENOSIS AND WAS 20 MM LONG WITH A REFERENCE VESSEL DIAMETER OF 3.0 MM. THE PHYSICIAN TREATED THE LESION WITH DIRECT STENT PLACEMENT OF A 3.0 X 32 MM TAXUS ELEMENT STENT. FOLLOWING POST-DILATATION, RESIDUAL STENOSIS WAS 0%. ON (B)(6) 2011, POST INDEX PROCEDURE, THE SUBJECT HAD ELEVATED TROPONIN VALUES AND AN MI WAS REPORTED. NO ACTION WAS TAKEN TO TREAT THIS EVENT AND THE PATIENT WAS DISCHARGED THE NEXT DAY ON ASPIRIN AND CLOPIDOGREL.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TAXUS¿ ELEMENT¿ CORONARY DRUG-ELUTING STENT NIQ BOSTON SCIENTIFIC - GALWAY H7493902532300 14234185

Patients

Seq Age Sex Outcome Treatment
1 77 YR Other